RELIANCE

RELIANCE

RELIANCE

Chronic Obstructive Pulmonary Disease (COPD) affects at least 15 million Americans and is one of the leading cause of death in the U.S. COPD exacerbations lead to about 700,000 hospitalizations in the U.S. each year.  Results from clinical trials and the recently published clinical guidelines indicate that long term use of either roflumilast or azithromycin significantly reduces the risk of COPD exacerbations.  No studies to date have directly compared long term roflumilast to azithromycin in patients with COPD, so it is unclear if one works better than the other.  The COPD Foundation’s Patient-Powered Research Network (PPRN) is leading a broad-based collaborative to conduct a large pragmatic trial called RELIANCE (RofLumilast or Azithromycin to preveNt COPD Exacerbations) to evaluate chronic roflumilast vs. azithromycin for the prevention of COPD exacerbations.

See why patients and clinicians are interested in the RELIANCE study:

Read More

Research like RELIANCE helps doctors decide which medications to prescribe to their patients, view video below: